Tier 2 — strong

Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency

Martina Huemer, Daria Diodato, Bernd Schwahn, Manuel Schiff, Anabela Bandeira, Jean-Francois Benoist, Alberto Burlina, Roberto Cerone, Maria L Couce, Angeles Garcia-Cazorla, Giancarlo la Marca, Elisabetta Pasquini, Laura Vilarinho, James D Weisfeld-Adams, Viktor Kožich, Henk Blom, Matthias R Baumgartner, Carlo Dionisi-Vici
Journal of inherited metabolic disease 2017 40(1):21-48

Bibliography

PubMed
PMID 27905001
PubMed Central
PMC5203859
DOI
10.1007/s10545-016-9991-4
Funding
Reported funding/support: European Union in the framework of the Health Program.2012_12_02
Competing interests
Reported disclosure: The authors of this guideline declare no competing interests but disclose the following: MRB has received financial support for attending E-HOD steering committee meetings from Orphan Europe. MRB and MH have received support from Milupa Metabolics for travel grants to develop a quality of life assessment tool for patients with intoxication type metabolic diseases. Charles University in Prague-First Faculty of Medicine received support from the Recordati Rare Disease Foundation for organizing an educational course on homocystinurias and methylation defects. MH, MRB, CDV, HB received speakers honoraria for their contribution to this educational course. The development of this guideline was part of the “European network and registry for homocystinurias and methylation defects (EHOD) project” (No.2012_12_02) which has received funding from the European Union in the framework of the Health Program. This article does not contain any studies with human or animal subjects performed by any of the authors.

Study snapshot

DesignClinical practice guideline
ModelEvidence synthesis; mixed research models
SampleExpert-reviewed literature on inherited remethylation disorders
InterventionHydroxocobalamin and/or betaine according to diagnosis
DurationLong-term disease management
EndpointsDiagnosis; Remethylation treatment; Early intervention

What the study showed, in plain terms

Published in 2017, this source examined prescription betaine and inherited metabolic disorders. Its evidence base was Expert-reviewed literature on inherited remethylation disorders. It evaluated Hydroxocobalamin and/or betaine according to diagnosis across Long-term disease management.

Early treatment is emphasized; betaine is recommended for severe MTHFR deficiency, while cobalamin-related defects require appropriate B12-based therapy.

Disease-specific guidance based largely on limited observational evidence. A later revised guideline should be consulted alongside this version.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • Early treatment is emphasized; betaine is recommended for severe MTHFR deficiency, while cobalamin-related defects require appropriate B12-based therapy.
  • The recorded outcome domains were Diagnosis; Remethylation treatment; Early intervention.

What this study can and cannot tell us

  • Disease-specific guidance based largely on limited observational evidence. A later revised guideline should be consulted alongside this version.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders
Giorgia Olivieri et al. · Journal of inherited metabolic disease · 2026
Tier 2
Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency
Andrew A M Morris et al. · Journal of inherited metabolic disease · 2017
Tier 4
Postauthorization safety study of betaine anhydrous
Ulrike Mütze et al. · Journal of inherited metabolic disease · 2022
Tier 4
Cystathionine beta synthase deficiency and brain edema associated with methionine excess under betaine supplementation: Four new cases and a review of the evidence
Bernd C Schwahn et al. · JIMD reports · 2020
Tier 2
Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial
Apolline Imbard et al. · Orphanet journal of rare diseases · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology